Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02143076 · ClinicalTrials.gov registry record

Medication Adherence in Youth With Sickle Cell Disease (SCD)

A clinical trial, sponsored by St. Jude Children's Research Hospital.

Completed
Registry status
36
Enrollment target

NCT02143076 is a clinical trial that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02143076 has completed, sponsored by St. Jude Children's Research Hospital.

COMPLETED
Registry status
36 participants
Enrollment target

Study Summary

Youth diagnosed with sickle cell disease (SCD) may have difficulty taking medication as prescribed (adherence). Hydroxyurea (HU) is one medication that youth may take to help manage SCD. Electronic adherence monitoring is widely considered the gold standard in objective adherence measurement. These monitors provide continuous, real-time records of medication adherence and reveal problematic behavior patterns, including underdosing, overdosing, delayed dosing, "drug holidays" (i.e. where individuals do not take medications for a specified interval of time), and "white coat" adherence (i.e., a pattern of drug adherence as a function of time where individuals display good adherence immediately before and after clinic attendance with worsening adherence in the period between). Overall, electronic adherence measures are considered valid, reliable, and accurate, with clear advantages over pharmacy refill records, physician estimates and self-report measures. Currently, only one electronic measure capable of monitoring medications in both pill and liquid form is being manufactured: WisePill and WiseBag. While data are limited regarding its validity and reliability, preliminary data support the use of Wise technology to measure adherence to medication. The current study will determine the Wise device's ability to feasibly measure adherence to liquid and solid form HU medication in a pediatric SCD population.

Interventions

  • BEHAVIORAL Demographic Questionnaire
  • BEHAVIORAL Medical Adherence Measure Questionnaire
  • BEHAVIORAL Acceptability Questionnaire

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2014-05
Est. Completion 2015-05

What the Registry Record Tells You About NCT02143076

The ClinicalTrials.gov registry entry for NCT02143076 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Demographic Questionnaire is the first listed.

NCT02143076 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02143076 about?

NCT02143076 is a clinical study titled "Medication Adherence in Youth With Sickle Cell Disease (SCD)". Youth diagnosed with sickle cell disease (SCD) may have difficulty taking medication as prescribed (adherence). Hydroxyurea (HU) is one medication that youth may take to help manage SCD. Electronic adherence monitoring is widely considered the gold standard in objective adherence measurement. These ...

What is the current status of trial NCT02143076?

This trial is currently completed. The enrollment target is 36 participants. The study started on 2014-05. Estimated completion is 2015-05.

What interventions are being tested in trial NCT02143076?

The interventions under investigation include: Demographic Questionnaire (BEHAVIORAL), Medical Adherence Measure Questionnaire (BEHAVIORAL), Acceptability Questionnaire (BEHAVIORAL).

Who is sponsoring clinical trial NCT02143076?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.